ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ:CKPT). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company's business, operations, and compliance policies, including allegations that: (i) Checkpoint had overstated its oversight and/or its establishment of adequate manufacturing standards and controls over its third-party contract manufacturers; (ii) accordingly, there were one or more issues with the Company's third-party contract manufacturing organization ("CMO") for cosibelimab; (iii) all the foregoing ...
CKPT) Class Action – Nationally Ranked Investors' Rights Firm Encourages Investors With Significant Losses to Contact the Firm>Full story available on Benzinga.com